TY - JOUR
T1 - Machine Learning Predictive Outcomes Modeling in Inflammatory Bowel Diseases
AU - Javaid, Aamir
AU - Shahab, Omer
AU - Adorno, William
AU - Fernandes, Philip
AU - May, Eve
AU - Syed, Sana
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. All rights reserved.
PY - 2022/6/1
Y1 - 2022/6/1
N2 - There is a rising interest in use of big data approaches to personalize treatment of inflammatory bowel diseases (IBDs) and to predict and prevent outcomes such as disease flares and therapeutic nonresponse. Machine learning (ML) provides an avenue to identify and quantify features across vast quantities of data to produce novel insights in disease management. In this review, we cover current approaches in ML-driven predictive outcomes modeling for IBD and relate how advances in other fields of medicine may be applied to improve future IBD predictive models. Numerous studies have incorporated clinical, laboratory, or omics data to predict significant outcomes in IBD, including hospitalizations, outpatient corticosteroid use, biologic response, and refractory disease after colectomy, among others, with considerable health care dollars saved as a result. Encouraging results in other fields of medicine support efforts to use ML image analysis - including analysis of histopathology, endoscopy, and radiology - to further advance outcome predictions in IBD. Though obstacles to clinical implementation include technical barriers, bias within data sets, and incongruence between limited data sets preventing model validation in larger cohorts, ML-predictive analytics have the potential to transform the clinical management of IBD. Future directions include the development of models that synthesize all aforementioned approaches to produce more robust predictive metrics.
AB - There is a rising interest in use of big data approaches to personalize treatment of inflammatory bowel diseases (IBDs) and to predict and prevent outcomes such as disease flares and therapeutic nonresponse. Machine learning (ML) provides an avenue to identify and quantify features across vast quantities of data to produce novel insights in disease management. In this review, we cover current approaches in ML-driven predictive outcomes modeling for IBD and relate how advances in other fields of medicine may be applied to improve future IBD predictive models. Numerous studies have incorporated clinical, laboratory, or omics data to predict significant outcomes in IBD, including hospitalizations, outpatient corticosteroid use, biologic response, and refractory disease after colectomy, among others, with considerable health care dollars saved as a result. Encouraging results in other fields of medicine support efforts to use ML image analysis - including analysis of histopathology, endoscopy, and radiology - to further advance outcome predictions in IBD. Though obstacles to clinical implementation include technical barriers, bias within data sets, and incongruence between limited data sets preventing model validation in larger cohorts, ML-predictive analytics have the potential to transform the clinical management of IBD. Future directions include the development of models that synthesize all aforementioned approaches to produce more robust predictive metrics.
UR - http://www.scopus.com/inward/record.url?scp=85131702465&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131702465&partnerID=8YFLogxK
U2 - 10.1093/ibd/izab187
DO - 10.1093/ibd/izab187
M3 - Article
C2 - 34417815
AN - SCOPUS:85131702465
SN - 1078-0998
VL - 28
SP - 819
EP - 829
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - 6
ER -